|
WO2021053185A1
|
|
Melflufen formulations and their use in the treatment or prophylaxis of osteosarcoma
|
|
GB202010259D0
|
|
Novel Treatments
|
|
GB202007930D0
|
|
Compounds
|
|
WO2020201542A1
|
|
Treatment of al amyloidosis with melflufen
|
|
GB201917908D0
|
|
Novel treatments
|
|
WO2020079165A1
|
|
Compounds containing deuterium
|
|
GB201913636D0
|
|
Novel treatments
|
|
GB201913633D0
|
|
Compounds
|
|
GB201911848D0
|
|
Compounds
|
|
GB201909695D0
|
|
Compounds
|
|
GB201905477D0
|
|
Novel formulations
|
|
GB201904714D0
|
|
Novel treatments
|
|
GB201816998D0
|
|
Compounds
|
|
GB201717050D0
|
|
Compounds
|
|
GB201521217D0
|
|
Dosage regimens
|
|
GB201521216D0
|
|
Dosage regimen
|
|
GB201507903D0
|
|
Process for preparation of nitrogen mustard derivatives
|
|
KR20200081440A
|
|
Lyophilized preparations of melphalan flufenamide
|
|
CN108685860A
|
|
Melphalan fluorine goes out the lyophilized preparation of amide
|
|
KR20200014947A
|
|
Lyophilized preparation of cytotoxic dipeptides
|
